Results 191 to 200 of about 35,682 (244)
Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases. [PDF]
ESC Heart FailWang J +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Multifaceted Mineralocorticoid Receptor
Comprehensive Physiology, 2014Abstract The primary adrenal cortical steroid hormones, aldosterone, and the glucocorticoids cortisol and corticosterone, act through the structurally similar mineralocorticoid (MR) and glucocorticoid receptors (GRs). Aldosterone is crucial for fluid, electrolyte, and hemodynamic homeostasis and tissue repair; the
Elise, Gomez-Sanchez +1 more
openaire +2 more sources
Mineralocorticoid receptor antagonists
Current Hypertension Reports, 2007With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan +1 more
openaire +3 more sources
Current Vascular Pharmacology, 2012
Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldosteronism observed in obese subjects
Ronconi, Vanessa +5 more
openaire +2 more sources
Several lines of evidence suggest a detrimental effect of aldosterone excess on the development of metabolic alterations. Glucose metabolism derangements due to aldosterone action are frequently observed not only in patients with primary aldosteronism but also in patients with obesity. A contribution to the hyperaldosteronism observed in obese subjects
Ronconi, Vanessa +5 more
openaire +2 more sources
Current Hypertension Reports, 2020
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta +2 more
openaire +2 more sources
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta +2 more
openaire +2 more sources
Evolution of the Mineralocorticoid Receptor
2019The mineralocorticoid receptor (MR) and its kin, the glucocorticoid receptor (GR) evolved from an ancestral corticoid receptor (CR) in a cyclostome (jawless fish) through gene duplication and divergence. Distinct MR and GR orthologs first appear in cartilaginous fishes, such as sharks, skates, rays and chimaeras.
Michael E, Baker, Yoshinao, Katsu
openaire +2 more sources
Mineralocorticoid Receptor Antagonists
2019Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
openaire +2 more sources
Mineralocorticoid receptors and hypertension
The Journal of Steroid Biochemistry and Molecular Biology, 1995Mineralocorticoid receptors (MR) have equal affinity for the mineralocorticoid aldosterone, and the physiological glucocorticoids cortisol and corticosterone. In epithelial tissues in vivo, MR are protected against glucocorticoid occupancy by the enzyme 11 beta-hydroxysteroid dehydrogenase, allowing access by the lower circulating levels of the ...
openaire +2 more sources
Adipocyte Mineralocorticoid Receptor
2019Mineralocorticoid receptor (MR) has been recently identified in adipose tissue, where its excessive activation contributes to several metabolic derangements often observed in obesity and metabolic syndrome. Recent findings support the existence of a bidirectional cross-talk between adipose tissue and adrenal glands, contributing to obesity-related ...
Infante M. +4 more
openaire +4 more sources